Your browser doesn't support javascript.
loading
Human organoids with an autologous tissue-resident immune compartment.
Recaldin, Timothy; Steinacher, Linda; Gjeta, Bruno; Harter, Marius F; Adam, Lukas; Kromer, Kristina; Mendes, Marisa Pimentel; Bellavista, Marina; Nikolaev, Mikhail; Lazzaroni, Giacomo; Krese, Rok; Kilik, Umut; Popovic, Doris; Stoll, Bilgenaz; Gerard, Régine; Bscheider, Michael; Bickle, Marc; Cabon, Lauriane; Camp, J Gray; Gjorevski, Nikolche.
Affiliation
  • Recaldin T; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
  • Steinacher L; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
  • Gjeta B; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.
  • Harter MF; Hannover Medical School, Institute of Immunology, Hannover, Germany.
  • Adam L; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.
  • Kromer K; University of Basel, Basel, Switzerland.
  • Mendes MP; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.
  • Bellavista M; Gustave Roussy Cancer Campus, University Paris-Saclay, Paris, France.
  • Nikolaev M; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.
  • Lazzaroni G; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.
  • Krese R; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
  • Kilik U; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.
  • Popovic D; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.
  • Stoll B; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
  • Gerard R; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.
  • Bscheider M; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.
  • Bickle M; University of Basel, Basel, Switzerland.
  • Cabon L; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.
  • Camp JG; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.
  • Gjorevski N; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.
Nature ; 2024 Aug 14.
Article in En | MEDLINE | ID: mdl-39143209
ABSTRACT
The intimate relationship between the epithelium and immune system is crucial for maintaining tissue homeostasis, with perturbations therein linked to autoimmune disease and cancer1-3. Whereas stem cell-derived organoids are powerful models of epithelial function4, they lack tissue-resident immune cells that are essential for capturing organ-level processes. We describe human intestinal immuno-organoids (IIOs), formed through self-organization of epithelial organoids and autologous tissue-resident memory T (TRM) cells, a portion of which integrate within the epithelium and continuously survey the barrier. TRM cell migration and interaction with epithelial cells was orchestrated by TRM cell-enriched transcriptomic programs governing cell motility and adhesion. We combined IIOs and single-cell transcriptomics to investigate intestinal inflammation triggered by cancer-targeting biologics in patients. Inflammation was associated with the emergence of an activated population of CD8+ T cells that progressively acquired intraepithelial and cytotoxic features. The appearance of this effector population was preceded and potentiated by a T helper-1-like CD4+ population, which initially produced cytokines and subsequently became cytotoxic itself. As a system amenable to direct perturbation, IIOs allowed us to identify the Rho pathway as a new target for mitigation of immunotherapy-associated intestinal inflammation. Given that they recapitulate both the phenotypic outcomes and underlying interlineage immune interactions, IIOs can be used to study tissue-resident immune responses in the context of tumorigenesis and infectious and autoimmune diseases.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Nature Year: 2024 Document type: Article Affiliation country: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Nature Year: 2024 Document type: Article Affiliation country: Switzerland